DR. REDDY’S LABORATORIES LTD

Hyderabad-based pharmaceutical company Dr. Reddy’s Laboratories earned a revenue of Rs 71 crore during FY 20-21 in the biopharma space, showing a decline of 10 per cent in its growth when compared to Rs 79 crore earned in FY 19-20. The year 2020 saw Dr. Reddy’s acquiring select anti-allergy brands from Glenmark Pharma. The company also announced its partnership with Biotechnology Industry Research Assistance Council (BIRAC) for advisory support on clinical trials of Sputnik V vaccine in India. In addition, the company launched Remdesivir, under a brand name Redyx, and Avigan (Favipiravir) 200 mg tablets in India for COVID-19 treatment.